Author

Peter Sabbatini

Observed names: P Sabbatini, P. Sabbatini, Peter A Sabbatini

Observed institutions: Rutgers, The State University of New Jersey, University of California, San Francisco, Cold Spring Harbor Laboratory, Bristol-Myers Squibb (United States), GlaxoSmithKline (United States), Rutgers Cancer Institute

ORCID: 0009-0007-8244-3700

Observed ORCID: 0009-0007-8244-3700

OpenAlex ID: A5034712498

The adenovirus E1A proteins induce apoptosis, which is inhibited by the E1B 19-kDa and Bcl-2 proteins.

1992 · L Rao, M Debbas, et al. · Proceedings of the National Academy of Sciences · 660

The E1B 19K protein blocks apoptosis by interacting with and inhibiting the p53-inducible and death-promoting Bax protein.

1996 · J Han, P Sabbatini, et al. · Genes & Development · 350

PDF

The 19-Kilodalton Adenovirus E1B Transforming Protein Inhibits Programmed Cell Death and Prevents Cytolysis by Tumor Necrosis Factor α

1992 · Eileen White, Peter Sabbatini, et al. · Molecular and Cellular Biology · 349

The polyproline region of p53 is required to activate apoptosis but not growth arrest

1997 · Daitoku Sakamuro, Peter Sabbatini, et al. · Oncogene · 316

Adenovirus E1B 19-kilodalton protein overcomes the cytotoxicity of E1A proteins

1991 · E White, R Cipriani, et al. · Journal of Virology · 243

Essential role for p53-mediated transcription in E1A-induced apoptosis.

1995 · P Sabbatini, J Lin, et al. · Genes & Development · 215

PDF

Induction of Apoptosis by Human Nbk/Bik, a BH3-Containing Protein That Interacts with E1B 19K

1996 · Jeonghoon Han, Peter Sabbatini, et al. · Molecular and Cellular Biology · 200

The 19-kilodalton adenovirus E1B transforming protein inhibits programmed cell death and prevents cytolysis by tumor necrosis factor alpha.

1992 · E White, P Sabbatini, et al. · Molecular and Cellular Biology · 195

Modulation of p53-Mediated Transcriptional Repression and Apoptosis by the Adenovirus E1B 19K Protein

1995 · Peter Sabbatini, Shiun-Kwei Chiou, et al. · Molecular and Cellular Biology · 191

Phosphoinositide 3-OH Kinase (PI3K) and PKB/Akt Delay the Onset of p53-mediated, Transcriptionally Dependent Apoptosis

1999 · Peter Sabbatini, Frank McCormick · Journal of Biological Chemistry · 141

A Phase Ib/II Trial of the First-in-Class Anti-CXCR4 Antibody Ulocuplumab in Combination with Lenalidomide or Bortezomib Plus Dexamethasone in Relapsed Multiple Myeloma

2019 · Irene M. Ghobrial, Chia-Jen Liu, et al. · Clinical Cancer Research · 103

GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancers

2009 · Peter Sabbatini, Susan Korenchuk, et al. · Molecular Cancer Therapeutics · 98

PDF

Inhibition of apoptosis in human immunodeficiency virus-infected cells enhances virus production and facilitates persistent infection

1995 · B A Antoni, P Sabbatini, et al. · Journal of Virology · 91

Ulocuplumab (BMS-936564 / MDX1338): a fully human anti-CXCR4 antibody induces cell death in chronic lymphocytic leukemia mediated through a reactive oxygen species-dependent pathway

2015 · Manoj K. Kashyap, Deepak Kumar, et al. · Oncotarget · 90

PDF

Antitumor Activity of GSK1904529A, a Small-molecule Inhibitor of the Insulin-like Growth Factor-I Receptor Tyrosine Kinase

2009 · Peter Sabbatini, Jason L. Rowand, et al. · Clinical Cancer Research · 80

PDF

MDMX Inhibits the p300/CBP-Mediated Acetylation of p53

2002 · Peter Sabbatini, Frank McCormick · DNA and Cell Biology · 62

Targeting the CXCR4 Pathway: Safety, Tolerability and Clinical Activity of Ulocuplumab (BMS-936564), an Anti-CXCR4 Antibody, in Relapsed/Refractory Acute Myeloid Leukemia

2014 · Pamela S. Becker, James M. Foran, et al. · Blood · 61

Interleukin 1 beta converting enzyme-like proteases are essential for p53-mediated transcriptionally dependent apoptosis.

1997 · P Sabbatini, J Han, et al. · PubMed · 59

Optimization of 4,6-bis-anilino-1H-pyrrolo[2,3-d]pyrimidine IGF-1R tyrosine kinase inhibitors towards JNK selectivity

2008 · Stanley D. Chamberlain, Anikó M. Redman, et al. · Bioorganic & Medicinal Chemistry Letters · 56

Slow Off-Rate Modified Aptamer (SOMAmer) as a Novel Reagent in Immunoassay Development for Accurate Soluble Glypican-3 Quantification in Clinical Samples

2018 · Jia Duo, Camelia Chiriac, et al. · Analytical Chemistry · 36

Discovery of 4,6-bis-anilino-1H-pyrrolo[2,3-d]pyrimidines: Potent inhibitors of the IGF-1R receptor tyrosine kinase

2008 · Stanley D. Chamberlain, Joseph W. Wilson, et al. · Bioorganic & Medicinal Chemistry Letters · 31

Discovery and optimization of imidazo[1,2-a]pyridine inhibitors of insulin-like growth factor-1 receptor (IGF-1R)

2008 · Kyle A. Emmitte, Brian J. Wilson, et al. · Bioorganic & Medicinal Chemistry Letters · 31

A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors

2025 · Geoffrey Ku, Lin Shen, et al. · Clinical Cancer Research · 24

PDF

Evaluation of antitumor properties of novel saframycin analogs in vitro and in vivo

2006 · Jeffrey R. Spencer, Martin Sendzik, et al. · Bioorganic & Medicinal Chemistry Letters · 16

Phase Ib Study of the Novel Anti-CXCR4 Antibody Ulocuplumab (BMS-936564) in Combination with Lenalidomide Plus Low-Dose Dexamethasone, or with Bortezomib plus Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma

2014 · Irene M. Ghobrial, Raymond Perez, et al. · Blood · 15

Works count: 89

Citation count: 3,795

H-index: 23

I10-index: 30